EU pharma warns against extending GMP directive to active substances
This article was originally published in SRA
Executive Summary
The pharmaceutical industry has expressed concern over a European Commission proposal to expand the scope of the EU directive on good manufacturing practice requirements to include the manufacturing of active pharmaceutical ingredients1,2.